Search

Shik Luen Paul Ip

Examiner (ID: 5172, Phone: (571)272-1941 , Office: P/2837 )

Most Active Art Unit
2837
Art Unit(s)
2837, 1931, 2828, 2107
Total Applications
3388
Issued Applications
3093
Pending Applications
44
Abandoned Applications
259

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 15422567 [patent_doc_number] => 10544197 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-28 [patent_title] => FGF-23 epitope peptide for improving resistance to breakage and eggshell strength [patent_app_type] => utility [patent_app_number] => 15/675022 [patent_app_country] => US [patent_app_date] => 2017-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 5014 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15675022 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/675022
FGF-23 epitope peptide for improving resistance to breakage and eggshell strength Aug 10, 2017 Issued
Array ( [id] => 12117313 [patent_doc_number] => 20180000898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'Method of Treating or Ameliorating Type 1 Diabetes Using FGF21' [patent_app_type] => utility [patent_app_number] => 15/671923 [patent_app_country] => US [patent_app_date] => 2017-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 27990 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15671923 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/671923
Method of Treating or Ameliorating Type 1 Diabetes Using FGF21 Aug 7, 2017 Abandoned
Array ( [id] => 12260612 [patent_doc_number] => 20180079806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-22 [patent_title] => 'CHIMERIC FIBROBLAST GROWTH FACTORS WITH ALTERED RECEPTOR SPECIFICITY' [patent_app_type] => utility [patent_app_number] => 15/668573 [patent_app_country] => US [patent_app_date] => 2017-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 42675 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15668573 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/668573
CHIMERIC FIBROBLAST GROWTH FACTORS WITH ALTERED RECEPTOR SPECIFICITY Aug 2, 2017 Abandoned
Array ( [id] => 12051208 [patent_doc_number] => 20170327551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'METHODS OF USING COMPOSITIONS COMPRISING FUSION VARIANTS OF FGF19 POLYPEPTIDES FOR REDUCING GLUCOSE LEVELS IN A SUBJECT' [patent_app_type] => utility [patent_app_number] => 15/666402 [patent_app_country] => US [patent_app_date] => 2017-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 32583 [patent_no_of_claims] => 74 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15666402 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/666402
Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject Jul 31, 2017 Issued
Array ( [id] => 12624552 [patent_doc_number] => 20180100014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => BINDING PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/659177 [patent_app_country] => US [patent_app_date] => 2017-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72936 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15659177 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/659177
Beta-klotho binding proteins Jul 24, 2017 Issued
Array ( [id] => 16169516 [patent_doc_number] => 10711066 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-14 [patent_title] => Anti-canine platelet derived growth factor receptor alpha antibody [patent_app_type] => utility [patent_app_number] => 16/318944 [patent_app_country] => US [patent_app_date] => 2017-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5240 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16318944 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/318944
Anti-canine platelet derived growth factor receptor alpha antibody Jul 19, 2017 Issued
Array ( [id] => 15256503 [patent_doc_number] => 20190376985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE [patent_app_type] => utility [patent_app_number] => 16/315805 [patent_app_country] => US [patent_app_date] => 2017-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16315805 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/315805
ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE Jul 6, 2017 Pending
Array ( [id] => 11977586 [patent_doc_number] => 20170281741 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'PEPTIDE AND METHOD FOR REDUCING THE PHOSPHATE REQUIREMENT AND EXCRETIION FROM FARM ANIMALS' [patent_app_type] => utility [patent_app_number] => 15/623450 [patent_app_country] => US [patent_app_date] => 2017-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 11425 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15623450 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/623450
FGF-23 epitope peptides and methods of use thereof Jun 14, 2017 Issued
Array ( [id] => 12980830 [patent_doc_number] => 20170342488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => METHODS OF USING FGF19 MODULATORS [patent_app_type] => utility [patent_app_number] => 15/608603 [patent_app_country] => US [patent_app_date] => 2017-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15608603 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/608603
METHODS OF USING FGF19 MODULATORS May 29, 2017 Abandoned
Array ( [id] => 17569932 [patent_doc_number] => 11318186 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-03 [patent_title] => Use of FGF21 in methods of increasing exocrine pancreatic secretion [patent_app_type] => utility [patent_app_number] => 16/304080 [patent_app_country] => US [patent_app_date] => 2017-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8132 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16304080 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/304080
Use of FGF21 in methods of increasing exocrine pancreatic secretion May 23, 2017 Issued
Array ( [id] => 14213969 [patent_doc_number] => 20190119369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => METHOD OF TREATING OR PREVENTING LIVER CONDITIONS [patent_app_type] => utility [patent_app_number] => 16/095021 [patent_app_country] => US [patent_app_date] => 2017-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24778 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16095021 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/095021
METHOD OF TREATING OR PREVENTING LIVER CONDITIONS Apr 20, 2017 Abandoned
Array ( [id] => 14309665 [patent_doc_number] => 20190144536 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => ASPROSIN, A FAST-INDUCED GLUCOGENIC PROTEIN HORMONE [patent_app_type] => utility [patent_app_number] => 16/092653 [patent_app_country] => US [patent_app_date] => 2017-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16092653 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/092653
ASPROSIN, A FAST-INDUCED GLUCOGENIC PROTEIN HORMONE Apr 12, 2017 Abandoned
Array ( [id] => 17274456 [patent_doc_number] => 20210380654 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/604088 [patent_app_country] => US [patent_app_date] => 2017-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11283 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604088 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/604088
HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF Apr 9, 2017 Pending
Array ( [id] => 11949494 [patent_doc_number] => 20170253646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'Functional Peptide Analogs of PEDF' [patent_app_type] => utility [patent_app_number] => 15/477934 [patent_app_country] => US [patent_app_date] => 2017-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 34283 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15477934 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/477934
Functional Peptide Analogs of PEDF Apr 2, 2017 Abandoned
Array ( [id] => 16570644 [patent_doc_number] => 20210009650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => MODIFIED FIBROBLAST GROWTH FACTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/089698 [patent_app_country] => US [patent_app_date] => 2017-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16089698 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/089698
MODIFIED FIBROBLAST GROWTH FACTORS AND USES THEREOF Mar 23, 2017 Abandoned
Array ( [id] => 11728044 [patent_doc_number] => 20170189486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/460917 [patent_app_country] => US [patent_app_date] => 2017-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 81 [patent_figures_cnt] => 81 [patent_no_of_words] => 89672 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15460917 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/460917
Therapeutic uses of modified FGF-21 polypeptides Mar 15, 2017 Issued
Array ( [id] => 11850282 [patent_doc_number] => 20170224774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'METHOD FOR USING SUPPLEMENTAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) OR ANALOG TO PREVENT OXYGEN INDUCED ARREST OF VESSEL GROWTH AND DISEASE SEQUELA OF PREMATURE INFANT BIRTH' [patent_app_type] => utility [patent_app_number] => 15/425872 [patent_app_country] => US [patent_app_date] => 2017-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1914 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15425872 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/425872
METHOD FOR USING SUPPLEMENTAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) OR ANALOG TO PREVENT OXYGEN INDUCED ARREST OF VESSEL GROWTH AND DISEASE SEQUELA OF PREMATURE INFANT BIRTH Feb 5, 2017 Abandoned
Array ( [id] => 11850283 [patent_doc_number] => 20170224775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'Lv PEPTIDE, ANTI-Lv ANTIBODY AND METHODS THEREOF' [patent_app_type] => utility [patent_app_number] => 15/424816 [patent_app_country] => US [patent_app_date] => 2017-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 8288 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15424816 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/424816
Lv PEPTIDE, ANTI-Lv ANTIBODY AND METHODS THEREOF Feb 3, 2017 Abandoned
Array ( [id] => 11618221 [patent_doc_number] => 20170128408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'NANOPARTICLE COMPLEXES OF PACLITAXEL, ALEMTUZUMAB, AND ALBUMIN' [patent_app_type] => utility [patent_app_number] => 15/414536 [patent_app_country] => US [patent_app_date] => 2017-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 20275 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414536 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/414536
Methods for treating CD52-expressing cancers using compositions comprising nanoparticle complexes of paclitaxel, alemtuzumab, and albumin Jan 23, 2017 Issued
Array ( [id] => 11618400 [patent_doc_number] => 20170128587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'NANOPARTICLE COMPLEXES OF ANTI-CD20 ANTIBODIES, ALBUMIN AND PACLITAXEL' [patent_app_type] => utility [patent_app_number] => 15/414526 [patent_app_country] => US [patent_app_date] => 2017-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 20273 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414526 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/414526
Nanoparticle complexes of rituximab, albumin and pacltaxel Jan 23, 2017 Issued
Menu